Investor Presentation - Q4 & FY26
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Camlin Fine Sciences reported Q4 FY26 revenue of Rs 4,248 mn and FY26 revenue of Rs 17,233 mn, up 6% YoY. However, profitability collapsed sharply — EBITDA margin fell to 5.0% in Q4 and 6.2% for FY26 versus 13.3% in FY25, driven by geopolitical conflict impacting raw material availability and costs, extended logistics, and a planned production switch from Methyl to Ethyl Vanillin. Additionally, internal Vanillin channel stock was liquidated in Q4, further compressing margins. The Straights business faced pricing pressure from increased local competition. Blends revenue grew 17% annually, with newly acquired Vinpai contributing Rs 165 mn in Q4. PAT from continuing operations turned negative at Rs -315 mn for FY26, though discontinued operations (CFS Europe and CFSWL liquidation) contributed a net gain of Rs 553 mn. Management outlook for FY27 is cautiously optimistic, expecting Vanillin improvement from US tariff withdrawal and continued Blends growth momentum.
The stock faces pressure as EBITDA margins nearly halved year-on-year due to raw material cost inflation and margin compression in the core Straights segment. However, the management signals margin improvement is expected in FY27 through higher Vanillin realisations and Blends growth, which could be positive if the geopolitical situation stabilises.